PROSPECTUS SUMMARY
This summary highlights information contained or incorporated by reference in this prospectus supplement. Because it is only a summary, it does not contain
all of the information that may be important to you or that you should consider before making an investment in our common stock. You should carefully read the entire prospectus and the accompanying prospectus, including the information contained
under the caption Risk Factors and elsewhere in our most recent Quarterly Report on Form 10-Q, the information under Risk Factors beginning on page
S-7 of this prospectus supplement and other information that we file from time to time with the SEC as well as the financial statements and related notes and the other information incorporated by reference
herein, before making an investment decision. See Where You Can Find More Information and Incorporation of Certain Documents By Reference in this prospectus supplement. This prospectus supplement may add to, update or change
information in the accompanying prospectus. Unless the context otherwise requires, all references in this prospectus supplement to Inovio, we, us, our, the Company or similar words refer to
Inovio Pharmaceuticals, Inc., together with our consolidated subsidiaries.
Our Company
We are a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases
associated with human papillomavirus, or HPV, cancer, and infectious diseases. Our DNA medicine pipeline is comprised of three types of product candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies. In clinical trials,
we have demonstrated that a DNA medicine can be delivered directly into cells in the body via our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens.
Our novel DNA medicine candidates are made using our proprietary SynCon® technology that creates
optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the persons immune system recognize and destroy cancerous or virally infected cells.
Our hand-held CELLECTRA® smart delivery devices provide optimized uptake of our DNA medicines within
the cell, overcoming a key limitation of other DNA-based technology approaches.
Human data to date have shown a
favorable safety profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA® smart device in more than 6,000 administrations across more than 2,000 patients.
Our corporate strategy is to advance, protect, and provide our novel DNA medicines to meet urgent and emerging global health needs. We continue to
advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. We aim to advance these candidates through commercialization and continue to leverage
third-party resources through collaborations and partnerships, including product license agreements.
Our partners and collaborators include ApolloBio
Corp., AstraZeneca, Beijing Advaccine, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense
Threat Reduction Agencys Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the
University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.
We or our collaborators are currently conducting or
planning clinical studies of our DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including
head & neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent